This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
Peakstone Realty Trust (PKST) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PKSTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
STMicroelectronics (STM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
STMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy ASML (ASML) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ASMLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How Hologic Leverages Its Financial Firepower to Drive Long-Term Value
by Moumi Mondal
Backed by robust profitability, HOLX deploys billions into acquisitions and repurchases to boost future earnings.
BDXNegative Net Change TMOPositive Net Change HOLXNegative Net Change
medical medical-devices
Is ISRG's Procedure Growth Enough to Offset Margin Pressures in 2025?
by Indrajit Bandyopadhyay
Intuitive Surgical raises 2025 procedure outlook after strong Q1 growth, but rising costs and tariff pressure weigh on margins.
MDTPositive Net Change SYKPositive Net Change ISRGPositive Net Change
medical medical-devices
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
by Debanjana Dey
HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
LLYPositive Net Change AMGNPositive Net Change HIMSPositive Net Change
medical medical-devices
GE HealthCare's Flyrcado Sets New Benchmark in Cardiac PET Imaging
by Zacks Equity Research
GEHC's Flyrcado gains momentum with FDA approval, CMS support, and expanding coverage in cardiac PET imaging.
PHGNegative Net Change NNOXNegative Net Change GEHCNegative Net Change
medical medical-devices
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
ANGOPositive Net Change CVSPositive Net Change QDELPositive Net Change ITGRNegative Net Change
medical medical-devices
Euroseas Ltd. (ESEA) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ESEAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
by Zacks Equity Research
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
ABTPositive Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices
Will CVS Health's Formulary Move Boost Its Weight Management Program?
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
UNHPositive Net Change NVONegative Net Change LLYPositive Net Change CVSPositive Net Change ELVNegative Net Change
medical medical-devices
FMS Stock Likely to Gain on New Optimization Plan FME Reignite
by Zacks Equity Research
Fresenius Medical Care unveils FME Reignite, targeting one billion euros in cost savings, tech upgrades and enhanced shareholder returns.
BAXNegative Net Change DVANo Net Change FMSNegative Net Change OMPositive Net Change
medical medical-devices
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
by Zacks Equity Research
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.
ABTPositive Net Change CVSPositive Net Change ITGRNegative Net Change BBNXNegative Net Change
medical medical-devices
Qiagen (QGEN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
QGENNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?
by Moumi Mondal
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
HOLXNegative Net Change COOPositive Net Change
medical medical-devices
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
by Zacks Equity Research
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
ANGOPositive Net Change SNNPositive Net Change CVSPositive Net Change ITGRNegative Net Change
medical medical-devices
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
ECLPositive Net Change ANGOPositive Net Change CVSPositive Net Change ITGRNegative Net Change
medical medical-devices
DXCM's Access Gains and Operational Strength Offset Margin Pressures
by Zacks Equity Research
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
ABTPositive Net Change MDTPositive Net Change DXCMNegative Net Change SENSPositive Net Change
medical medical-devices
Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building?
by Moumi Mondal
TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.
EXASNegative Net Change VSTMNegative Net Change GHPositive Net Change TEMPositive Net Change
medical medical-devices
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
by Indrajit Bandyopadhyay
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
CERTNegative Net Change DOCSPositive Net Change GEHCNegative Net Change
medical medical-devices
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
by Debanjana Dey
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
TDOCNegative Net Change AMWLNegative Net Change HIMSPositive Net Change
medical medical-devices
After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AGENPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sportsman's Warehouse (SPWH)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SPWHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks Initiates Coverage of Retractable Technologies With Underperform Recommendation
by Debanjana Dey
Discover why Zacks rates Retractable Technologies as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore RVP's declining profitability amid rising costs, significant cash concerns and concentration risk.
RVPPositive Net Change
medical medical-devices
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
by Zacks Equity Research
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
QGENNegative Net Change CORPositive Net Change PAHCPositive Net Change HIMSPositive Net Change
medical medical-devices